Product Description
Ifetroban is a potent and selective thromboxane receptor antagonist, and has been studied in other diseases. This drug is aimed at cardiac function and has shown to be effective in other cardiac indications. The current study aims to address the unmet medical need to treat Duchenne cardiomyopathy using a new therapeutic strategy for patients with Duchenne muscular dystrophy. (Sourced from: https://www.parentprojectmd.org/drug-development-pipeline/ifetroban/)
Mechanisms of Action: TXA2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Muscular Dystrophy, Duchenne *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Cumberland
Company Location: Western America
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: India, United States
Active Clinical Trial Count: 4
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Cumberland presented P2 Muscular Dystrophy, Duchenne results on 2025-03-19 for Ifetroban
- Clinical Outcomes Reported - Cumberland presented P2 Muscular Dystrophy, Duchenne results on 2025-02-04 for Ifetroban
Highest Development Phases
Phase 2: Cardiomyopathy, Dilated|Hypertension, Pulmonary|Idiopathic Pulmonary Fibrosis|Muscular Dystrophy, Duchenne|Oncology Solid Tumor Unspecified|Scleroderma, Diffuse|Scleroderma, Limited|Scleroderma, Localized
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05571059 |
CPI-IFE-008 | P2 |
Recruiting |
Idiopathic Pulmonary Fibrosis |
2027-01-01 |
12% |
2026-02-05 |
|
NCT02682511 |
SSc-PAH | P2 |
Active, not recruiting |
Scleroderma, Localized|Scleroderma, Limited|Hypertension, Pulmonary|Scleroderma, Diffuse |
2026-02-01 |
12% |
2025-07-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03694249 |
VICC MD1854 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-04-01 |
31% |
2024-06-28 |
Primary Endpoints |
NCT03340675 |
DMD | P2 |
Completed |
Muscular Dystrophy, Duchenne|Cardiomyopathy, Dilated |
2024-03-06 |
50% |
2026-03-18 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/17/2026 |
News Article |
Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting |
|
02/04/2026 |
News Article |
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program |
|
12/08/2025 |
News Article |
CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT |
|
10/28/2025 |
News Article |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE |